Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The PARP inhibitor Lynparza slows disease progression in women with BRCA-related ovarian cancer.
Tecentriq combo slows progression of hard-to-treat breast cancer.
The FDA recently approved Vitrakvi for all cancers with specific gene mutation.
Bavencio or Keytruda plus targeted therapy slowed disease progression in Phase III studies.
Rubraca shrank tumors and lowered PSA levels in men with advanced prostate cancer.
Tecentriq plus chemotherapy delays disease progression or death in people with metastatic triple-negative breast cancer.
PARP inhibitor demonstrates unprecedented improvement in progression-free survival.
Larotrectinib and entrectinib are effective against cancer with specific genetic changes anywhere in the body.
Treatment with Opdivo appears to work well for HIV-positive people in small study.
Analysis of a week’s worth of tweets paints a mixed picture of by individuals and institutions.
Hormone therapy is safe in men with breast cancer, but side effects remain a challenge.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.